Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by OneAscent Wealth Management LLC

OneAscent Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 5,992 shares of the biopharmaceutical company’s stock after purchasing an additional 288 shares during the quarter. OneAscent Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $325,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of Nova Scotia lifted its position in Bristol-Myers Squibb by 13.7% during the third quarter. Bank of Nova Scotia now owns 208,970 shares of the biopharmaceutical company’s stock valued at $12,129,000 after purchasing an additional 25,153 shares during the period. Morningstar Investment Services LLC lifted its position in Bristol-Myers Squibb by 87.4% during the third quarter. Morningstar Investment Services LLC now owns 7,849 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 3,660 shares during the period. CWA Asset Management Group LLC lifted its position in Bristol-Myers Squibb by 3.6% during the third quarter. CWA Asset Management Group LLC now owns 8,107 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 283 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in Bristol-Myers Squibb by 1,004.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 94,351 shares of the biopharmaceutical company’s stock valued at $5,476,000 after purchasing an additional 85,812 shares during the period. Finally, Waverly Advisors LLC lifted its position in Bristol-Myers Squibb by 11.5% during the third quarter. Waverly Advisors LLC now owns 10,485 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 1,078 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 0.0 %

Shares of NYSE BMY opened at $41.53 on Friday. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The stock has a market cap of $84.19 billion, a PE ratio of -13.40, a P/E/G ratio of 14.20 and a beta of 0.43. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The company has a 50-day moving average of $42.97 and a 200 day moving average of $48.14.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the prior year, the company earned $2.05 EPS. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BMY. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. BMO Capital Markets decreased their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Finally, Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.